Published in J Biol Chem on December 20, 2002
Protein kinase C isoforms: Multi-functional regulators of cell life and death. Front Biosci (Landmark Ed) (2009) 1.93
Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells. Mol Biol Cell (2005) 1.28
Human rhomboid family-1 gene RHBDF1 participates in GPCR-mediated transactivation of EGFR growth signals in head and neck squamous cancer cells. FASEB J (2008) 1.21
Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor. Br J Pharmacol (2009) 0.99
Gastrointestinal growth factors and hormones have divergent effects on Akt activation. Cell Signal (2009) 0.92
Bile acid-induced epidermal growth factor receptor activation in quiescent rat hepatic stellate cells can trigger both proliferation and apoptosis. J Biol Chem (2009) 0.88
CCK1 and CCK2 receptors are expressed on pancreatic stellate cells and induce collagen production. J Biol Chem (2010) 0.86
Crosstalk Between MAPK/ERK and PI3K/AKT Signal Pathways During Brain Ischemia/Reperfusion. ASN Neuro (2015) 0.86
Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research. Int J Mol Sci (2016) 0.85
The Src kinase Yes is activated in pancreatic acinar cells by gastrointestinal hormones/neurotransmitters, but not pancreatic growth factors, which stimulate its association with numerous other signaling molecules. Biochim Biophys Acta (2012) 0.81
BRET Biosensor Analysis of Receptor Tyrosine Kinase Functionality. Front Endocrinol (Lausanne) (2013) 0.81
Disruption of the murine protein kinase Cbeta gene promotes gallstone formation and alters biliary lipid and hepatic cholesterol metabolism. J Biol Chem (2011) 0.81
Inhibition of the equilibrative nucleoside transporter 1 and activation of A2A adenosine receptors by 8-(4-chlorophenylthio)-modified cAMP analogs and their hydrolytic products. J Biol Chem (2009) 0.80
Ras activation in response to phorbol ester proceeds independently of the EGFR via an unconventional nucleotide-exchange factor system in COS-7 cells. Biochem J (2006) 0.79
The Src family kinase Fyn mediates hyperosmolarity-induced Mrp2 and Bsep retrieval from canalicular membrane. J Biol Chem (2011) 0.77
Elucidation of the roles of the Src kinases in pancreatic acinar cell signaling. J Cell Biochem (2015) 0.77
CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells. J Mol Neurosci (2015) 0.76
Cholecystokinin receptors in Atlantic salmon: molecular cloning, gene expression, and structural basis. Physiol Rep (2013) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (2007) 6.12
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology (2008) 5.07
Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol (2007) 4.70
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology (2007) 4.44
Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology (2009) 3.89
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (2009) 3.35
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology (2011) 3.24
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology (2003) 3.09
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol (2013) 2.89
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology (2009) 2.79
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology (2006) 2.78
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54
Occult hepatitis C: how convincing are the current data? Hepatology (2009) 2.49
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol (2005) 2.45
Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol (2011) 2.40
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology (2007) 2.37
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol (2010) 2.35
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology (2009) 2.35
Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis (2005) 2.33
Antiviral strategies in hepatitis C virus infection. J Hepatol (2012) 2.25
The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov (2007) 2.24
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology (2010) 2.20
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology (2005) 2.19
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med (2012) 2.14
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol (2013) 2.08
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol (2012) 2.05
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology (2008) 2.03
Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat Chem Biol (2009) 2.00
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology (2010) 1.96
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol (2011) 1.91
Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology (2012) 1.89
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (2003) 1.86
Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol (2008) 1.82
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol (2010) 1.82
Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol (2006) 1.77
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology (2009) 1.76
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer (2005) 1.75
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology (2010) 1.70
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One (2011) 1.69
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol (2008) 1.69
Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. Hepatology (2013) 1.68
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol (2013) 1.68
Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int (2008) 1.68
Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol (2011) 1.66
Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. J Cyst Fibros (2013) 1.66
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol (2008) 1.65
New kinetic models for the hepatitis C virus. Hepatology (2005) 1.63
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health (2009) 1.62
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology (2010) 1.61
Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int (2012) 1.60
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol (2006) 1.60
Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol (2013) 1.57
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int (2008) 1.56
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res (2008) 1.56
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut (2010) 1.55
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol (2011) 1.55
Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology (2002) 1.55
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol (2006) 1.54
Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell (2008) 1.52